IDEAYA Biosciences grants 260,200 inducement stock options at $36.4 per sharePUBT·11 hours agoIDYA-2.47%
IDEAYA Biosciences, Inc. $IDYA Shares Sold by Redmile Group LLCMarket Beat·2 days ago, 04:53 AMIDYA-2.47%
IDEAYA Biosciences: Buy Rating Reiterated as Precision Oncology Pipeline Advances and $62 Price Target MaintainedTip Ranks·Jul 27 at 06:55 AMIDYA-2.47%
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers | IDYA Stock NewsStockTitan·Jul 26 at 09:00 PMIDYA-2.47%
IDEAYA shares ESMO 2026 data updates for darovasertib trials in uveal melanomaPUBT·Jul 17 at 08:00 AMIDYA-2.47%01276-0.52%
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs | IDYA Stock NewsStockTitan·Jul 17 at 12:00 AMIDYA-2.47%600276-1.04%
IDEAYA Biosciences Chief Accounting Officer Andres Ruiz Briseno sells 9,550 shares for $382,131.94PUBT·Jul 9 at 03:57 PMIDYA-2.47%
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index InclusionSimplywall·Jul 3 at 03:01 AMIDYA-2.47%
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | IDYA Stock NewsStockTitan·Jun 25 at 09:00 PMIDYA-2.47%
